Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia

Condition:   Schizophrenia Interventions:   Drug: SEP-363856;   Drug: Placebo Sponsor:   Sumitomo Dainippon Pharma Co., Ltd. Recruiting

Source: ClinicalTrials.gov - March 30, 2020 Category: Research Source Type: clinical trials